^
Association details:
Biomarker:KRAS G12C
Cancer:Melanoma
Drug:Lumakras (sotorasib) (KRAS G12C inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Non Small Cell Lung Cancer)
New
Title:

LUMAKRAS® (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

Excerpt:
Amgen...announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer (NSCLC) that has progressed after systemic anticancer therapy.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

Published date:
09/20/2020
Excerpt:
We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation….Responses were also observed in patients with pancreatic, endometrial, and appendiceal cancers and melanoma….Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation.
DOI:
10.1056/NEJMoa1917239
Trial ID: